ISSN:
1432-1912
Keywords:
Hemodynamics
;
Oxygen Consumption
;
L 6150
;
Hydralazine
;
Dog
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary The systemic and coronary hemodynamic effects of the new antihypertensive agent L 6150 (3-hydrazino-6-[N,N-bis(2-hydroxyethyl) amino]pyridazine) have been investigated in anesthetized and unanesthetized dogs, in comparison with hydralazine. The depressor effect induced by L 6150 is due to a fall of peripheral resistance and, in conscious animals, is accompanied by an increase of cardiac output and heart rate, suggesting that the main activity of the drug is related to a vasodilator effect. The compound was shown to markedly increase coronary blood flow. This effect, which in conscious dogs can be explained, at least in part, on the basis of an increased myocardial metabolism, was observed to occur in anesthetized animals even in conditions of reduced cardiac output and myocardial oxygen consumption. In anesthetized dogs the same systemic, hemodynamic modifications were induced by L 6150 and by higher doses of hydralazine. Furthermore the percent increase of coronary blood flow induced by L 6150 was significantly higher than that induced by hydralazine, for the same degree of modifications of myocardial oxygen uptake. In conscious dogs, L 6150 induced the same systemic hemodynamic modifications as hydralazine with the exception of heart rate, which was increased more by the former drug. The coronary blood flow increase was more marked following L 6150 than following hydralazine, even when the two drugs induced the same increase of cardiac output.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00500608
Permalink
